Svetlana V. Turkina

Svetlana V. Turkina

Auto-generated profile, based on publicly available information

Svetlana V. Turkina

Volgograd State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2025 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
ODOxana M. Drapkina
Oxana M. Drapkina
MMM. V. Maevskaya
M. V. Maevskaya
KRK. L. Raikhelson
K. L. Raikhelson
SOSergey Okovityi
Sergey Okovityi
ЮУЮ. П. Успенский
Ю. П. Успенский
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.

20 May 2023 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
VGV. B. Grinevich
V. B. Grinevich
LLL. B. Lazebnik
L. B. Lazebnik
YKYu. A. Kravchuk
Yu. A. Kravchuk
VRV. G. Radchenko
V. G. Radchenko
ETE. I. Tkachenko
E. I. Tkachenko
AKAnatoly Khavkin
Anatoly Khavkin
Summary Post- COVID syndrome refers to the long-term consequences of a new coronavirus infection COVID-19, which includes a set of symptoms that develop or persist after COVID-19. Symptoms of gastrointestinal disorders in post- COVID syndrome, due to chronic infl ammation, the consequences of organ damage, prolonged hospitalization, social isolation, and other causes, can be persistent and require a multidisciplinary approach. The presented clinical practice guidelines consider the main preventive and therapeutic and diagnostic approaches to the management of patients with gastroenterological manifestations of postCOVID syndrome. The Guidelines were approved by the 17th National Congress of Internal Medicine and the 25th Congress of Gastroenterological Scientifi c Society of Russia.

23 December 2021 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
LLL. B. Lazebnik
L. B. Lazebnik
STS. V. Turkina
S. V. Turkina
Non-alcoholic fatty liver disease (NAFLD) is considered not only as a disease with poor hepatic prognosis. The problem has acquired a multidisciplinary problem. The variety of concomitant diseases and pathological conditions are united by common pathophysiological mechanisms.This review summarizes and presents the data available in the modern literature on the association of NAFLD with cardiovascular diseases, type 2 diabetes mellitus, polycystic ovary syndrome, chronic kidney disease, etc. The role of the liver in the homeostasis of the organism and the pathogenetic mechanisms of the formation of NAFLD-associated comorbidity are discussed.

18 October 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
MSM. E. Statsenko
M. E. Statsenko
STS. V. Turkina
S. V. Turkina
YLYu. E. Lopushkova
Yu. E. Lopushkova
The article reviews the efficacy of meldonium in patients with various diseases, which are based on secondary mitochondrial dysfunction. Mitochondria are complex cellular organelles that control many metabolic processes, including fatty acid oxidation, the Krebs cycle, oxidative phosphorylation in the electron transport chain, and many other processes. Many conditions can lead to secondary mitochondrial dysfunction and affect other diseases. Damage to mitochondria can promote the activation of free radical processes and the initiation of the mechanisms of programmed cell death, mitochondrial dysfunction decrease in the immune response, increase in the activity of the body’s inflammatory response in various infections. Mitochondria appear to be important in COVID-19 pathogenesis because of its role in innate antiviral immunity, as well as inflammation. The article presents data on the effectiveness of using meldonium as a drug that helps to arrest pathological processes in mitochondria. The main mechanism of action of meldonium is based on a decrease in L-carnitine levels and increase of peroxisomes activity in the cytosol Meldonium was designed as a inhibitor of carnitine biosynthesis aimed to prevent accumulation of cytotoxic intermediate products of fatty acid beta- oxidation in ischemic tissues and to block this highly oxygen- consuming process. It is based on the correction of the energy metabolism of the cell. There was a positive trend in the use of meldonium in patients with diseases of the cardiovascular system (chronic ischemic diseases, chronic heart failure, arterial hypertension, etc.), neurological disorders (stroke, cerebrovascular insufficiency, etc.), respiratory diseases. The data on the beneficial effect of meldonium on the immune response in patients with coronavirus, bronchial asthma, chronic obstructive pulmonary disease, during vaccination with anti-influenza serum are presented. A decrease in asthenia was noted against the background of the use of meldonium in patients who had undergone coronavirus infection.

9 October 2023 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
LLL. B. Lazebnik
L. B. Lazebnik
STS. V. Turkina
S. V. Turkina
The gut microbiota regulates critical processes in host metabolism and physiology. Understanding the formation of relationships between the gut microbiome, liver, and other organs under physiological conditions, as well as under the influence of microbiota-damaging factors, provides important insights into the pathophysiology of not only liver diseases, but also the complex level of communication and the role of the microbiome in the gut-liver-brain, gut-liver-kidney, gut-liver-lung, and gut-liver-heart axes.

30 December 2024 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
IMIgor V. Maev
Igor V. Maev
VAV. A. Akhmedov
V. A. Akhmedov
LVL. G. Vologzhanina
L. G. Vologzhanina
ADA. I. Dolgushina
A. I. Dolgushina
ЮЦЮ. В. Цыганова
Ю. В. Цыганова
Лекарственные поражения печени (ЛПП) у взрослых